| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Edrecolomab Basic information |
| Product Name: | Edrecolomab | | Synonyms: | Edrecolomab;17-1A;Immunoglobulin G 2A (mouse monoclonal 17-1A gamma-chain anti-human colon canceer tumor-associated antigen), disulfide with mouse monoclonal 17-1A light chain, dimer;Immunoglobulin G2A, anti-(human colon cancer tumor-associated antigen) (mouse monoclonal 17-1A gamma2A-chain), disulfide with mouse monoclonal 17-1A light chain, dimer;Panorex;Research Grade Edrecolomab(DHD17403);Research Grade Edrecolomab | | CAS: | 156586-89-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Edrecolomab Structure]() |
| | Edrecolomab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Edrecolomab Usage And Synthesis |
| Uses | Monoclonal antibody (antineoplastic adjuvant). | | Brand name | Panorex (Centocor). | | in vivo | Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model[1]. | Animal Model: | Male nu/nu mice injected with HT-29 colon carcinoma cells[1] | | Dosage: | 30 μg/dose | | Administration: | Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation | | Result: | Inhibited tumor growth with a number of significant readings (p≤0.05). |
|
| | Edrecolomab Preparation Products And Raw materials |
|